BCLI vs. KZR, FGEN, MRNS, INKT, ALLK, SCLX, CALC, GRCE, SRZN, and OKUR
Should you be buying Brainstorm Cell Therapeutics stock or one of its competitors? The main competitors of Brainstorm Cell Therapeutics include Kezar Life Sciences (KZR), FibroGen (FGEN), Marinus Pharmaceuticals (MRNS), MiNK Therapeutics (INKT), Allakos (ALLK), Scilex (SCLX), CalciMedica (CALC), Grace Therapeutics (GRCE), Surrozen (SRZN), and OnKure Therapeutics (OKUR). These companies are all part of the "pharmaceutical products" industry.
Brainstorm Cell Therapeutics vs.
Brainstorm Cell Therapeutics (NASDAQ:BCLI) and Kezar Life Sciences (NASDAQ:KZR) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their analyst recommendations, earnings, institutional ownership, risk, dividends, media sentiment, valuation, profitability and community ranking.
Brainstorm Cell Therapeutics' return on equity of 0.00% beat Kezar Life Sciences' return on equity.
Brainstorm Cell Therapeutics currently has a consensus target price of $30.00, indicating a potential upside of 2,442.37%. Kezar Life Sciences has a consensus target price of $39.50, indicating a potential upside of 885.04%. Given Brainstorm Cell Therapeutics' stronger consensus rating and higher probable upside, equities research analysts plainly believe Brainstorm Cell Therapeutics is more favorable than Kezar Life Sciences.
In the previous week, Brainstorm Cell Therapeutics had 6 more articles in the media than Kezar Life Sciences. MarketBeat recorded 10 mentions for Brainstorm Cell Therapeutics and 4 mentions for Kezar Life Sciences. Kezar Life Sciences' average media sentiment score of 0.91 beat Brainstorm Cell Therapeutics' score of -0.30 indicating that Kezar Life Sciences is being referred to more favorably in the news media.
Brainstorm Cell Therapeutics has a beta of 0.35, indicating that its share price is 65% less volatile than the S&P 500. Comparatively, Kezar Life Sciences has a beta of 0.61, indicating that its share price is 39% less volatile than the S&P 500.
Brainstorm Cell Therapeutics received 154 more outperform votes than Kezar Life Sciences when rated by MarketBeat users. Likewise, 59.03% of users gave Brainstorm Cell Therapeutics an outperform vote while only 57.08% of users gave Kezar Life Sciences an outperform vote.
14.3% of Brainstorm Cell Therapeutics shares are held by institutional investors. Comparatively, 67.9% of Kezar Life Sciences shares are held by institutional investors. 6.7% of Brainstorm Cell Therapeutics shares are held by insiders. Comparatively, 10.4% of Kezar Life Sciences shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.
Brainstorm Cell Therapeutics has higher earnings, but lower revenue than Kezar Life Sciences. Kezar Life Sciences is trading at a lower price-to-earnings ratio than Brainstorm Cell Therapeutics, indicating that it is currently the more affordable of the two stocks.
Summary
Brainstorm Cell Therapeutics beats Kezar Life Sciences on 9 of the 15 factors compared between the two stocks.
Get Brainstorm Cell Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for BCLI and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Brainstorm Cell Therapeutics Competitors List
Related Companies and Tools
This page (NASDAQ:BCLI) was last updated on 5/22/2025 by MarketBeat.com Staff
